Target Information

Target General Infomation
Target ID
T45993
Former ID
TTDS00163
Target Name
Calcium channel
Target Type
Successful
Disease Arrhythmia [ICD9: 427; ICD10: I47-I49]
Angina pectoris [ICD9: 413; ICD10: I20]
Allergy [ICD9: 995.3; ICD10: T78.4]
Alzheimer disease [ICD9: 331; ICD10: G30]
Bipolar disorder [ICD9: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8, 300; ICD10: F31, F40-F42]
Cardiac arrhythmias [ICD9: 427; ICD10: I47-I49]
Chronic stable angina [ICD9: 413; ICD10: I20]
Cerebral vasospasm [ICD9: 443.9; ICD10: I73.9]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Cardiovascular disorder [ICD10: I00-I99]
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63]
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21]
Epilepsy [ICD10: G40]
Glaucoma [ICD9: 365; ICD10: H40-H42]
Hyperinsulinemia [ICD10: E16.1]
Hypertension [ICD9: 401; ICD10: I10-I16]
Heart failure [ICD9: 428; ICD10: I50]
Heart arrhythmia [ICD10: I47-I49]
High blood pressure; Angina [ICD9: 401, 413; ICD10: I10, I11, I12, I13, I15, I20]
Irritable bowel syndrome [ICD9: 564.1, 787.91; ICD10: A09, K58, K59.1]
Nerve injury [ICD10: T14.4]
Psoriasis [ICD9: 696; ICD10: L40]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
Unspecified [ICD code not available]
BioChemical Class
Voltage-gated ion channel
Target Validation
T45993
Drugs and Mode of Action
Drug(s) Bepridil Drug Info Approved Chronic stable angina [536095], [539481]
Clevidipine butyrate Drug Info Approved Hypertension [529941], [530865]
Felodipine Drug Info Approved Hypertension [467526], [538304]
Isradipine Drug Info Approved Hypertension [467728], [538323]
Nicardipine Drug Info Approved High blood pressure; Angina [538588], [539652]
Nimodipine Drug Info Approved Cerebral vasospasm [537115], [539643]
Nisoldipine Drug Info Approved Hypertension [538334], [539644]
DIPROTEVERINE HYDROCHLORIDE Drug Info Phase 3 Angina pectoris [530977]
Arverapamil Drug Info Phase 2 Irritable bowel syndrome [536224]
HBI-3000 Drug Info Phase 2 Heart arrhythmia [523241]
Nexopamil Drug Info Phase 2 Hypertension [533605]
S-2150 Drug Info Phase 2 Angina pectoris [525742]
CM2489 Drug Info Phase 1 Psoriasis [550394]
Elpetrigine Drug Info Phase 1 Bipolar disorder [548658]
YM-16151-4 Drug Info Phase 1 Hypertension [533693]
Rycals Drug Info Preclinical Heart failure [548909]
AE-0047 Drug Info Discontinued in Preregistration Hypertension [545033]
Monatepil maleate Drug Info Discontinued in Preregistration Angina pectoris [544922]
Palonidipine hydrochloride Drug Info Discontinued in Preregistration Hypertension [544802]
Semotiadil Drug Info Discontinued in Preregistration Hypertension [544577]
Anipamil Drug Info Discontinued in Phase 3 Hypertension [544597]
ELGODIPINE HYDROCHLORIDE Drug Info Discontinued in Phase 3 Angina pectoris [544620]
S-12968 Drug Info Discontinued in Phase 3 Hypertension [544583]
Tetrandrine Drug Info Discontinued in Phase 3 Colorectal cancer [548123]
AM336 Drug Info Discontinued in Phase 2 Pain [547107]
BRL-32872A Drug Info Discontinued in Phase 2 Cardiac arrhythmias [544642]
CD-349 Drug Info Discontinued in Phase 2 Hypertension [544582]
Dopropidil Drug Info Discontinued in Phase 2 Angina pectoris [544651]
FLOSATIDIL Drug Info Discontinued in Phase 2 Angina pectoris [546027]
Levosemotiadil Drug Info Discontinued in Phase 2 Cardiac arrhythmias [545959]
LIFARIZINE HYDROCHLORIDE Drug Info Discontinued in Phase 2 Nerve injury [545611]
S-312-d Drug Info Discontinued in Phase 2 Epilepsy [545128]
TAMOLARIZINE HYDROCHLORIDE Drug Info Discontinued in Phase 2 Cognitive disorders [544615]
CEREBROCRAST Drug Info Discontinued in Phase 1 Nerve injury [546142]
CERM-11956 Drug Info Discontinued in Phase 1 Angina pectoris [544570]
IGANIDIPINE HYDROCHLORIDE Drug Info Discontinued in Phase 1 Glaucoma [544613]
KT-362 Drug Info Discontinued in Phase 1 Heart arrhythmia [544621]
NP-252 Drug Info Discontinued in Phase 1 Hypertension [544612]
SM-6586 Drug Info Discontinued in Phase 1 Hypertension [545247]
SR-33805 Drug Info Discontinued in Phase 1 Angina pectoris [545199]
AHR-16303B Drug Info Terminated Hypertension [528509]
AHR-16462B Drug Info Terminated Hypertension [544614]
AJ-3941 Drug Info Terminated Cerebrovascular ischaemia [545131]
CD-832 Drug Info Terminated Angina pectoris [544928]
Clentiazem Drug Info Terminated Angina pectoris [544573]
Darodipine Drug Info Terminated Cerebrovascular ischaemia [544644]
DHP-218 Drug Info Terminated Hypertension [544647]
E-2050 Drug Info Terminated Cerebrovascular ischaemia [547437]
Emopamil Drug Info Terminated Cerebrovascular ischaemia [534257]
LAS-30538 Drug Info Terminated Hyperinsulinemia [526783]
NALTIAZEM HYDROCHLORIDE Drug Info Terminated Angina pectoris [544616]
NNC-09-0026 Drug Info Terminated Cerebrovascular ischaemia [545623]
NS-638 Drug Info Terminated Cerebrovascular ischaemia [545919]
NS-649 Drug Info Terminated Alzheimer disease [545918]
NS-696 Drug Info Terminated Epilepsy [545920]
Pranidipine Drug Info Terminated Angina pectoris [544610]
RS-93522 Drug Info Terminated Hypertension [545315]
RWJ-22108 Drug Info Terminated Allergy [545176]
RWJ-37868 Drug Info Terminated Epilepsy [546547]
SB-206284A Drug Info Terminated Cerebrovascular ischaemia [546310]
SB-237376 Drug Info Terminated Arrhythmia [526551]
SDZ-249482 Drug Info Terminated Pain [546809]
SIM-6080 Drug Info Terminated Angina pectoris [544566]
Siratiazem Drug Info Terminated Angina pectoris [545039]
SKF-96365 Drug Info Terminated Angina pectoris [539569], [544629]
SQ-33351 Drug Info Terminated Hypertension [545248]
UK-51656 Drug Info Terminated Cardiovascular disorder [545465]
VUF-8929 Drug Info Terminated Heart failure [546655]
Z-6568 Drug Info Terminated Hypertension [546236]
ZM-224832 Drug Info Terminated Hypertension [545336]
Modulator AE-0047 Drug Info [534512]
AGN-190744 Drug Info
AHR-16303B Drug Info [528509]
AHR-16462B Drug Info [551574]
AJ-3941 Drug Info [534300]
AM336 Drug Info
Anipamil Drug Info [526808]
Arverapamil Drug Info
BELFOSDIL Drug Info
Bepridil Drug Info [556264]
BRL-32872A Drug Info
CD-349 Drug Info [533370]
CD-832 Drug Info [534624]
CD-832.HCL Drug Info
Clentiazem Drug Info
Clevidipine butyrate Drug Info [529941], [530865]
CM2489 Drug Info
Darodipine Drug Info [533171]
DHP-218 Drug Info [532637]
Dopropidil Drug Info [531675]
E-2050 Drug Info
Emopamil Drug Info [534257]
Isradipine Drug Info [556264]
KT-362 Drug Info [528634]
LAS-30538 Drug Info [526783]
leualacin Drug Info
Levosemotiadil Drug Info [525617]
Monatepil maleate Drug Info [533755]
NNC-09-0026 Drug Info [533857]
NS-638 Drug Info [534103]
NS-649 Drug Info [534454]
NS-696 Drug Info [545921]
Palonidipine hydrochloride Drug Info [533987]
Pranidipine Drug Info [534602]
RWJ-22108 Drug Info [534679]
RWJ-37868 Drug Info [546548]
Rycals Drug Info [544149]
S-2150 Drug Info [525742]
SB-206284A Drug Info [534379]
SB-237376 Drug Info [526551]
SDZ-249482 Drug Info [544057]
Siratiazem Drug Info [533657]
SKF-96365 Drug Info [531001]
SQ-33351 Drug Info [545249]
SR-33805 Drug Info [533840]
SR-33805A Drug Info [534181], [551871]
UK-51656 Drug Info [531460]
VUF-8929 Drug Info [534538]
YM-16151-4 Drug Info [533693]
Z-6568 Drug Info [534223]
ZM-224832 Drug Info [533916]
Inhibitor CEREBROCRAST Drug Info [530538], [551871]
Antagonist CERM-11956 Drug Info [533437], [551871]
DIPROTEVERINE HYDROCHLORIDE Drug Info [534306], [551871]
FLOSATIDIL Drug Info [551871]
SM-6586 Drug Info [533969]
Tetrandrine Drug Info [529052]
Agonist ELGODIPINE HYDROCHLORIDE Drug Info [527236], [551871]
Blocker Elpetrigine Drug Info [551057]
Felodipine Drug Info [536912]
HBI-3000 Drug Info [531239]
IGANIDIPINE HYDROCHLORIDE Drug Info [525666], [551871]
LIFARIZINE HYDROCHLORIDE Drug Info [534011], [551871]
NALTIAZEM HYDROCHLORIDE Drug Info [529043], [551871]
Nexopamil Drug Info [533605]
Nicardipine Drug Info [537568]
Nimodipine Drug Info [537329]
Nisoldipine Drug Info [537487]
NP-252 Drug Info [529006], [551871]
RS-93522 Drug Info [530703], [551871]
S-12968 Drug Info [530048]
S-312-d Drug Info [526987]
Semotiadil Drug Info [525787]
SIM-6080 Drug Info [534236], [551871]
TAMOLARIZINE HYDROCHLORIDE Drug Info [525821], [551871]
TELUDIPINE HYDROCHLORIDE Drug Info [533748], [551871]
References
Ref 467526(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4190).
Ref 467728(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4488).
Ref 523241ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health.
Ref 525742Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
Ref 526551Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
Ref 526783The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5.
Ref 528509AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
Ref 5299412008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
Ref 530865Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010 May;30(5):515-28.
Ref 530977Diproteverine (BRL 40015): a new type of calcium antagonist with potential antianginal properties. Eur J Pharmacol. 1991 Jan 17;192(3):317-27.
Ref 533605Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
Ref 533693Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
Ref 534257Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54.
Ref 536095New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
Ref 536224Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
Ref 537115Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
Ref 538304FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075896.
Ref 538323FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077169.
Ref 538334FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 079051.
Ref 538588FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022276.
Ref 539481(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2337).
Ref 539569(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2441).
Ref 539643(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2523).
Ref 539644(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2524).
Ref 539652(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2559).
Ref 544566Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000149)
Ref 544570Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000166)
Ref 544573Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000188)
Ref 544577Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000198)
Ref 544582Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000220)
Ref 544583Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000221)
Ref 544597Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000258)
Ref 544610Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000287)
Ref 544612Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000291)
Ref 544613Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000292)
Ref 544614Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000297)
Ref 544615Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000299)
Ref 544616Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000300)
Ref 544620Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000324)
Ref 544621Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000337)
Ref 544629Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000362)
Ref 544642Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000403)
Ref 544644Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000417)
Ref 544647Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000422)
Ref 544651Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000432)
Ref 544802Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001157)
Ref 544922Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001558)
Ref 544928Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001566)
Ref 545033Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001931)
Ref 545039Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001949)
Ref 545128Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002235)
Ref 545131Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002238)
Ref 545176Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002359)
Ref 545199Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002436)
Ref 545247Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002576)
Ref 545248Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
Ref 545315Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002793)
Ref 545336Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002886)
Ref 545465Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003366)
Ref 545611Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003892)
Ref 545623Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003940)
Ref 545918Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005353)
Ref 545919Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005354)
Ref 545920Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355)
Ref 545959Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005516)
Ref 546027Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005965)
Ref 546142Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006562)
Ref 546236Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007046)
Ref 546310Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007384)
Ref 546547Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896)
Ref 546655Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009533)
Ref 546809Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010408)
Ref 547107Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013107)
Ref 547437Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016308)
Ref 548123Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022136)
Ref 548658Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027454)
Ref 548909Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030217)
Ref 550394Clinical pipeline report, company report or official report of CalciMedica (2011).
Ref 525617Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33.
Ref 525666Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. CurrEye Res. 2000 Feb;20(2):101-8.
Ref 525742Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80.
Ref 525787Thyroid hypertrophic effect of semotiadil fumarate, a new calcium antagonist, in rats. J Toxicol Sci. 2000 May;25(2):121-30.
Ref 525821Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8.
Ref 526551Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.
Ref 526783The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5.
Ref 526808Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):339-44.
Ref 526987Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65.
Ref 527236The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004 Oct;18(13):1516-23.
Ref 528509AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53.
Ref 528634Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604.
Ref 529006Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol.1991 Oct 22;203(3):337-44.
Ref 529043Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 Sep;35(9):2071-5.
Ref 529052Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31.
Ref 5299412008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
Ref 530048(+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br J Pharmacol. 1991 Jul;103(3):1703-8.
Ref 530538The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can J Physiol Pharmacol. 2009 Nov;87(11):923-32.
Ref 530703Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5.
Ref 530865Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy. 2010 May;30(5):515-28.
Ref 531001The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75.
Ref 531239Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.
Ref 531460Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. J Med Chem. 1990 Feb;33(2):585-91.
Ref 531675Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol. 1990 Sep 1;66(5):636-41.
Ref 532637Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. J Cardiovasc Pharmacol. 1987 Sep;10(3):274-9.
Ref 533171Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+. Br J Pharmacol. 1989 Dec;98(4):1303-11.
Ref 533370A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62.
Ref 533437The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. Eur J Pharmacol. 1988 May 10;149(3):195-203.
Ref 533605Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
Ref 533657Comparison of the effects of diltiazem and its analogue siratiazem on contractility in arteries, ileum and cardiac muscle. J Auton Pharmacol. 1995 Apr;15(2):107-13.
Ref 533693Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
Ref 533748Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33.
Ref 533755Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens. 1994 Oct;7(10 Pt 2):131S-40S.
Ref 533840Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52.
Ref 533857Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav. 1994 May;48(1):77-85.
Ref 533916Diuretic and antihypertensive activity of ZENECA ZM224,832: a novel eukalemic diuretic with calcium channel blocking activity. Pharmacology. 1994 Mar;48(3):167-75.
Ref 533969Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Jpn J Pharmacol. 1993 Oct;63(2):165-9.
Ref 533987Effect of palonidipine hydrochloride (TC-81), a novel calcium antagonist, on the canine coronary artery. Nihon Yakurigaku Zasshi. 1993 Jul;102(1):23-33.
Ref 534011The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7.
Ref 534103Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60.
Ref 534181Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43.
Ref 534223Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative-ion mass spectrometry. J Mass Spectrom. 1996 Sep;31(9):994-1002.
Ref 534236Determination of the calcium antagonist SIM6080 and its N- and O-demethylated metabolites in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 9;676(1):77-85.
Ref 534257Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54.
Ref 534300Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303.
Ref 534306Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
Ref 534379The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab. 1997 Apr;17(4):421-9.
Ref 534454Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31.
Ref 534512AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997 Sep;29(3):337-43.
Ref 534538In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Arzneimittelforschung. 1997 Nov;47(11):1211-8.
Ref 534602Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem. 1998 Jan;178(1-2):335-43.
Ref 534624Effects of CD-832, a new calcium antagonist, on intracranial pressure in anesthetized dogs. Life Sci. 1998;62(19):PL283-8.
Ref 534679Design and discovery of RWJ 22108--a novel bronchoselective calcium channel blocker. Drug Des Discov. 1998 May;15(3):135-48.
Ref 536912Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. Epub 2008 Oct 30.
Ref 537329Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
Ref 537487RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
Ref 537568Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
Ref 544057Physiology and Pharmacology of the Vanilloid Receptor. Curr Neuropharmacol. 2006 January; 4(1): 1-15.
Ref 544149Fixing ryanodine receptor Ca2+ leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010 SUMMER; 7(2): e151-e157.
Ref 545249Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577)
Ref 545921Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355)
Ref 546548Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896)
Ref 551057Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
Ref 551574A pharmacological and biochemical examination of AHR-16462B, a novel calcium antagonist coronary vasodilator/antihypertensive. Drug Development Research. 01/1991; 22(3):259-271.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.